Search results for "Highlights"
SGLT2 inhibitors may have class effect for reduction of cardiac risk
The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
https://diabetes.acponline.org/archives/2017/06/09/3.htm
9 Jun 2017
Spotlight on diabetes incidence and complications
Mortality and cardiovascular complications from diabetes have gone down, but incidence rates among youth are up, according to recent studies of Swedish and American patients, respectively.
https://diabetes.acponline.org/archives/2017/04/14/5.htm
14 Apr 2017
Liraglutide may offer high-risk patients protection from CV events, death, study finds
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of liraglutide per day via injection or placebo in addition to standard care.
https://diabetes.acponline.org/archives/2016/07/15/1.htm
15 Jul 2016
Oral glucose tolerance test results may be influenced by height, study finds
Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.
https://diabetes.acponline.org/archives/2017/06/09/2.htm
9 Jun 2017
Intensive BP control associated with worse CV outcomes in type 2 diabetes and recent ACS
A post hoc analysis found that patients with baseline systolic blood pressure (BP) <120 mm Hg or >160 mm Hg or follow-up BP <130 mm Hg had a significantly increased risk for a composite outcome of death from cardiovascular (CV) causes, nonfatal myocardial infarction, and nonfatal stroke.
https://diabetes.acponline.org/archives/2018/11/09/1.htm
9 Nov 2018
Approved drugs for diabetic neuropathy better than placebo, review finds
In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
https://diabetes.acponline.org/archives/2017/04/14/2.htm
14 Apr 2017
One-hour glucose tolerance test outperforms two-hour test for predicting progression to diabetes
Machine learning was used to combine different variables, including clinical risk factors, plasma glucose and insulin levels, HbA1c level, and six metabolic markers, in 1,527 models for predicting progression risk.
https://diabetes.acponline.org/archives/2018/12/14/1.htm
14 Dec 2018
Screening tool identifies high-risk drivers with type 1 diabetes and website helps to avoid future accidents
Significant independent predictors of risk for driving mishaps included annual driving distance and presence of peripheral neuropathy. Researchers developed an 11-item questionnaire to further refine risk prediction.
https://diabetes.acponline.org/archives/2017/05/12/3.htm
12 May 2017
Treatment deintensification uncommon in type 2 diabetes
Less than a quarter of patients with an HbA1c below 6.0% had a drug discontinued or a dosage decreased, even after the American Diabetes Association issued a practice advisory about the risk of mortality associated with intensive glucose control.
https://diabetes.acponline.org/archives/2017/05/12/2.htm
12 May 2017
Higher prevalence of complications in young adults diagnosed with type 2 vs. type 1 diabetes
Compared to those with type 1 diabetes, participants with type 2 had a significantly higher age-adjusted prevalence of diabetic kidney disease, retinopathy, peripheral, arterial stiffness, and hypertension by age 21.
https://diabetes.acponline.org/archives/2017/03/10/3.htm
10 Mar 2017